diff --git a/inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md b/inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md
similarity index 98%
rename from inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md
rename to inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md
index edd359659..b0cc28ba8 100644
--- a/inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md
+++ b/inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md
@@ -7,10 +7,11 @@ date: 2026-02-17
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: null-result
 priority: high
 tags: [psilocybin, treatment-resistant-depression, Phase-3, clinical-trial, mental-health, psychedelic-therapy, FDA, NDA, Compass-Pathways]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content